

Ashutosh Chilkoti is the Alan L. Kaganov Professor and the Chair of the Department of Biomedical Engineering at Duke University. His areas of research include genetically encoded materials and biointerface science. He has published ~300 papers, has been cited ~30,000 times, has a Google Scholar H-index of 93, and has 30 patents awarded and 50 in process. Prof. Chilkoti was awarded the *Clemson Award for Contributions to the Literature* by the Society for Biomaterials in 2011, the *Robert A. Pritzker Distinguished Lecture award* by the Biomedical Engineering Society in 2013, was elected to the *National Academy of Inventors* in 2014, received the *Distinguished Alumni award* from the Indian Institute of Technology, Delhi in 2015, and the *Diamond award* from the College of Engineering at the University of Washington in 2017. He is the founder of five start-up companies: PhaseBio Pharmaceuticals, a publicly traded company on NASDAQ (ticker: PHAS) that is taking drug delivery technology that he developed into clinical trials, Sentilus, a clinical diagnostics company that was acquired by Immucor in 2014, BioStealth, a spinoff of Sentilus, GatewayBio, that is commercializing a next-generation PEGylation technology for biologics, Isolere Bio that is developing a non-chromatographic technology for purification of monoclonal antibodies, and inSoma Bio that is developing a recombinant protein matrix for tissue reconstruction.